6 research outputs found
Supporting international students to meet assessment expectations
This paper offers practical suggestions for teaching strategies that will assist international students. A case study is presented involving the delivery of an introductory engineering unit at the Perth Institute of Business and Technology. The approach detailed allowed the academic staff to identify areas of concern in students’ learning early in the semester. Detecting and addressing these issues led to a signifi cant improvement in preparing these students to meet the exam requirements
Using online and multimedia resources to enhance the student learning experience in a telecommunications laboratory within an Australian university
A comparison of misoprostol vaginal insert and misoprostol vaginal tablets for induction of labor in nulliparous women: a retrospective cohort study
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The IMAGE trial
Objectives: Rituximab is an effective treatment in patients with established rheumatoid arthritis (RA). The Objective: of the IMAGE study was to determine the effi cacy of rituximab in the prevention of joint damage and its safety in combination with methotrexate (MTX) in patients initiating treatment with MTX. Methods: In this double-blind randomised controlled phase III study, 755 MTX-naĂŻve patients with active RA were randomly assigned to MTX alone, rituximab 2Ă—500 mg + MTX or rituximab 2Ă—1000 mg + MTX. The primary end point at week 52 was the change in joint damage measured using a Genant-modified Sharp score. Results: 249, 249 and 250 patients were randomly assigned to MTX alone, rituximab 2Ă—500 mg + MTX or rituximab 2Ă—1000 mg + MTX, respectively. At week 52, treatment with rituximab 2Ă—1000 mg + MTX compared with MTX alone was associated with a reduction in progression of joint damage (mean change in total modified Sharp score 0.359 vs 1.079; p=0.0004) and an improvement in clinical outcomes (ACR50 65% vs 42%; p<0.0001); rituximab 2Ă—500 mg + MTX improved clinical outcomes (ACR50 59% vs 42%; p<0.0001) compared with MTX alone but did not signifi cantly reduce the progression of joint damage. Safety outcomes were similar between treatment groups. Conclusions: Treatment with rituximab 2Ă—1000 mg in combination with MTX is an effective therapy for the treatment of patients with MTX-naĂŻve RA
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
Rituximab is an effective treatment in patients with established rheumatoid arthritis (RA). The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of joint damage and its safety in combination with methotrexate (MTX) in patients initiating treatment with MTX
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
Rituximab is an effective treatment in patients with established rheumatoid arthritis (RA). The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of joint damage and its safety in combination with methotrexate (MTX) in patients initiating treatment with MTX.In this double-blind randomised controlled phase III study, 755 MTX-naĂŻve patients with active RA were randomly assigned to MTX alone, rituximab 2Ă—500 mg + MTX or rituximab 2Ă—1000 mg + MTX. The primary end point at week 52 was the change in joint damage measured using a Genant-modified Sharp score.249, 249 and 250 patients were randomly assigned to MTX alone, rituximab 2Ă—500 mg + MTX or rituximab 2Ă—1000 mg + MTX, respectively. At week 52, treatment with rituximab 2Ă—1000 mg + MTX compared with MTX alone was associated with a reduction in progression of joint damage (mean change in total modified Sharp score 0.359 vs 1.079; p=0.0004) and an improvement in clinical outcomes (ACR50 65\% vs 42\%; p<0.0001); rituximab 2Ă—500 mg + MTX improved clinical outcomes (ACR50 59\% vs 42\%; p<0.0001) compared with MTX alone but did not significantly reduce the progression of joint damage. Safety outcomes were similar between treatment groups.Treatment with rituximab 2Ă—1000 mg in combination with MTX is an effective therapy for the treatment of patients with MTX-naĂŻve RA. ClinicalTrials.gov identifier NCT00299104